Menu

More Mini Brains

Simple versions of brain organoids could serve as new models for testing the effects of drugs, researchers reported at this year’s AAAS meeting. 

Feb 17, 2016
Jef Akst

THOMAS HARTUNG/JOHNS HOPKINSMini brains, or orbs of neurons typically derived from human fibroblasts intended to better recapitulate human brain function than rodent models, just got simpler. At the annual meeting of the American Association for the Advancement of Science (AAAS) in Washington, DC, last week (February 12), Johns Hopkins University toxicologist Thomas Hartung described his group’s latest versions of these increasingly popular brain organoids, which have recently been used to study Down syndrome and autism, among other disorders, are only 350 micrometers in diameter—about the size of a housefly’s eye—yet contain multiple types of neurons, as well as astrocytes and oligodendrocytes.

The mini brains are smaller and more standardized than previous versions, Hartung said, comparing previous versions to Ferraris and Maseratis and his own to Mini Coopers, Science News reported. “We don’t have the first brain model nor are we claiming to have the best one,” Hartung said in a press release. “But this is the most standardized one. And when testing drugs, it is imperative that the cells being studied are as similar as possible to ensure the most comparable and accurate results.”

Hartung and colleagues now working to patent the mini brains and launch a company called Organome to produce them. The researchers hope to begin production this year. “Only when we can have brain models like this in any lab at any time will we be able to replace animal testing on a large scale,” Hartung said in the press release.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.